drugset
drugset / Trial / NCT06103773

A Study of Single and Multiple Oral Doses of TollB-001

NCT06103773 ↗

Phase 1 Unknown 122 enrolled Toll Biotech Co. Ltd. (Beijing)
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to evaluate the safety and tolerability of TollB-001 following the administration of single or multiple oral doses in healthy adult subjects

Timeline

Start
2023-09-28
Primary completion
2024-06-09
Completion
2024-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TollB-001 Small molecule 50 mg Oral
Subject TollB-001 Small molecule 100 mg Oral
Subject TollB-001 Small molecule 200 mg Oral
Subject TollB-001 Small molecule 400 mg Oral
Subject TollB-001 Small molecule 800 mg Oral
Subject TollB-001 Small molecule 1000 mg Oral

Indications

rheumatoid arthritis